Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy Transcript

SA Transcripts157.4K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy December 17, 2025 1:00 PM EST Company Participants Linda Marbán - Co-Founder, President, CEO & DirectorMark Awadalla - Chief Development OfficerMicheal Binks - Chief Medical OfficerCraig McDonald Conference Call Participants Jonathan H.

Soslow Presentation Unknown Executive So hi, everyone. Welcome to today's webinar with PPMD, where we're joined by Capricor Therapeutics, who are providing a community update on their Phase 3 trial, HOPE-3, which was evaluating their investigational product, deramiocel for treatment of Duchenne muscular dystrophy. I'm Eric Camino, I'm PPMD's Vice President of Research and Clinical Innovation. I'm also joined on the call today by one of our regulatory consultants, Steve Zook, who's the Chair at Faegre Drinker Consulting. Also on the line, we have Dr. Craig McDonald from UC Davis and Dr. Jon Soslow, from Vanderbilt Children's Hospital. And then from the Capricor team, we are joined by their CEO, Linda Marban, their Chief Medical Officer, Michael Binks; and their Chief Development Officer, Mark Awadalla. As we go through the presentation, if you have any questions, we will have an open Q&A at the end. So there is a chat function at the bottom of your screen. You can submit questions to that. We also had some questions submitted ahead of the webinar. We'll try to get to as many of those as we can during that portion. We are also recording this webinar. So if you have to step away or if there's someone who this would be relevant to, it will be posted to PPMD's websites. You can always come back and take another look or share it with someone who this might be relevant to. But I think with that, we can get started. So